Anti-zika virus activity of polyoxometalates

Francese, Rachele; Civra, Andrea; Rittá, Massimo; Donalisio, Manuela; Argenziano, Monica; Cavalli, Roberta; Mougharbel, Ali S.; Kortz, Ulrich; Lembo, David

doi:10.1016/j.antiviral.2019.01.005

Cited by 24 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previously, other polyphenols, such as delphinidin and epigallocatechin gallate, have been shown to have antiflaviviral effects [25]. Our data have demonstrated that the isolated ellagic acid inhibited, in vitro, the infection of 2 lineages, the African one, which is responsible for more acute infection, and Asian ZIKV, which is associated with neurological impairments [26]. Interestingly, the compound also exerted adulticidal activity against Aedes aegypti mosquito, the main vector of the virus [27].…”

Section: Resultsmentioning

confidence: 57%

“…Two ZIKV strains were used to investigate the antiviral potential of pomegranate: the 1947 Uganda MR766 and the 2013 French Polynesia HPF2013, representing the African and the Asian lineages respectively. The viruses were produced via the transfection of 293T cells with 2 plasmids (pCDNA6.2 Zika MR766 In-tron3115 HDVr MEG 070916 5 and pCDNA6.2 Zika HPF2013 3864,9388Intron HDVr MEG091316 2) kindly provided by Prof. F. Di Cunto and Prof. M. J. Evans, and were propagated and titered in Vero cells, as described in Francese et al [26]. The HSV-2 strain (ATCC VR-540) was propagated, collected, and titrated, via plaque assay, on Vero cells [33].…”

Section: Virusesmentioning

confidence: 99%

See 1 more Smart Citation

Punica granatum Leaf Ethanolic Extract and Ellagic Acid as Inhibitors of Zika Virus Infection

et al. 2020

Self Cite

View full text Add to dashboard Cite

Zika virus, an arthropod-borne flavivirus, is an emerging healthcare threat worldwide. Zika virus is responsible for severe neurological effects, such as paralytic Guillain-Barrè syndrome, in adults, and also congenital malformations, especially microcephaly. No specific antiviral drugs and vaccines are currently available, and treatments are palliative, but medicinal plants show great potential as natural sources of anti-Zika phytochemicals. This study deals with the investigation of the composition, cytotoxicity, and anti-Zika activity of Punica granatum leaf ethanolic extract, fractions, and phytoconstituents. P. granatum leaves were collected from different areas in Italy and Greece in different seasons. Crude extracts were analyzed and fractionated, and the pure compounds were isolated. The phytochemical and biomolecular fingerprint of the pomegranate leaves was determined. The antiviral activities of the leaf extract, fractions, and compounds were investigated against the MR766 and HPF2013 Zika virus strains in vitro. Both the extract and its fractions were found to be active against Zika virus infection. Of the compounds isolated, ellagic acid showed particular anti-Zika activities, with EC50 values of 30.86 µM for MR766 and 46.23 µM for HPF2013. The mechanism of action was investigated using specific antiviral assays, and it was demonstrated that ellagic acid was primarily active as it prevented Zika virus infection and was able to significantly reduce Zika virus progeny production. Our data demonstrate the anti-Zika activity of pomegranate leaf extract and ellagic acid for the first time. These findings identify ellagic acid as a possible anti-Zika candidate compound that can be used for preventive and therapeutic interventions.

show abstract

Section: Resultsmentioning

confidence: 57%

Section: Virusesmentioning

confidence: 99%

Punica granatum Leaf Ethanolic Extract and Ellagic Acid as Inhibitors of Zika Virus Infection

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…Two strains of infectious Zika viruses (1947 Uganda MR766 and 2013 French Polynesia HPF2013) were generated by transfection of 293T cells with two plasmids (pCDNA6.2 Zika MR766 Intron3115 HDVr MEG 070916 5 and pCDNA6.2 Zika HPF2013 3864,9388Intron HDVr MEG091316 2) as previously described [49]. The viruses were then propagated in Vero cells and titrated by plaque assay.…”

Section: Virusesmentioning

confidence: 99%

“…Unbound viruses were then washed, serial dilutions of colostrum (from 1:3 to 1: 6561) were added to cells and the plates were incubated at 37˚C to allow virus entry. After the viral entry, the treatment was aspirated and viral particles still present on the cell surface were inactivated by a wash with citrate buffer (citric acid 40 mM, potassium chloride 10 mM, sodium chloride 135 mM, pH 3) for 1 minute at room temperature, as previously described [49]. Cells were then washed with warm medium 3 times and overlaid with 1.2% methycellulose medium (ZIKV entry assay) for 72h or with fresh medium (USUV entry assay) for 24h.…”

Section: Entry Assaymentioning

confidence: 99%

Anti-Zika virus and anti-Usutu virus activity of human milk and its components

et al. 2020

Self Cite

View full text Add to dashboard Cite

The benefits of human milk are mediated by multiple nutritional, trophic, and immunological components, able to promote infant's growth, maturation of its immature gut, and to confer protection against infections. Despite these widely recognized properties, breast-feeding represents an important mother-to-child transmission route of some viral infections. Different studies show that some flaviviruses can occasionally be detected in breast milk, but their transmission to the newborn is still controversial. The aim of this study is to investigate the antiviral activity of human milk (HM) in its different stages of maturation against two emerging flaviviruses, namely Zika virus (ZIKV) and Usutu virus (USUV) and to verify whether HMderived extracellular vesicles (EVs) and glycosaminoglycans (GAGs) contribute to the milk protective effect. Colostrum, transitional and mature milk samples were collected from 39 healthy donors. The aqueous fractions were tested in vitro with specific antiviral assays and EVs and GAGs were derived and characterized. HM showed antiviral activity against ZIKV and USUV at all the stages of lactation with no significant differences in the activity of colostrum, transitional or mature milk. Mechanism of action studies demonstrated that colostrum does not inactivate viral particles, but it hampers the binding of both flaviviruses to cells. We also demonstrated that HM-EVs and HM-GAGs contribute, at least in part, to the anti-ZIKV and anti-USUV action of HM. This study discloses the intrinsic antiviral activity of HM against ZIKV and USUV and demonstrates the contribution of two bioactive components in mediating its protective effect. Since the potential infectivity of HM during ZIKV and USUV infection is still unclear, these data support the World Health Organization recommendations about breast-feeding during ZIKV infection and could contribute to producing new guidelines for a possible USUV epidemic.

show abstract

“…Porphyrins like Co-protoporphyrin IX (CoPPIX) and Sn-protoporphyrin IX (SnPPIX) induce viral envelope protein loss, affecting viral morphology and entry into target cells [81]. Benzoxazine monomer derived carbon dots (BZM-CDs) [82], polyoxometalates (POMs) [83], cyanohydrazones [84], synthetic carbohydrate receptors (SCRs) [85], and some other small molecules [86,87,88] also inhibit ZIKV infection in cell culture, and reduce viral replication in mice [89].…”

Section: Antiviralsmentioning

confidence: 99%

Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go

Saiz

2019

Pharmaceuticals

View full text Add to dashboard Cite

Zika virus (ZIKV) is a mosquito-borne flavivirus that spread throughout the American continent in 2015 causing considerable worldwide social and health alarm due to its association with ocular lesions and microcephaly in newborns, and Guillain–Barré syndrome (GBS) cases in adults. Nowadays, no licensed vaccines or antivirals are available against ZIKV, and thus, in this very short time, the scientific community has conducted enormous efforts to develop vaccines and antivirals. So that, different platforms (purified inactivated and live attenuated viruses, DNA and RNA nucleic acid based candidates, virus-like particles, subunit elements, and recombinant viruses) have been evaluated as vaccine candidates. Overall, these vaccines have shown the induction of vigorous humoral and cellular responses, the decrease of viremia and viral RNA levels in natural target organs, the prevention of vertical and sexual transmission, as well as that of ZIKV-associated malformations, and the protection of experimental animal models. Some of these vaccine candidates have already been assayed in clinical trials. Likewise, the search for antivirals have also been the focus of recent investigations, with dozens of compounds tested in cell culture and a few in animal models. Both direct acting antivirals (DAAs), directed to viral structural proteins and enzymes, and host acting antivirals (HAAs), directed to cellular factors affecting all steps of the viral life cycle (binding, entry, fusion, transcription, translation, replication, maturation, and egress), have been evaluated. It is expected that this huge collaborative effort will produce affordable and effective therapeutic and prophylactic tools to combat ZIKV and other related still unknown or nowadays neglected flaviviruses. Here, a comprehensive overview of the advances made in the development of therapeutic measures against ZIKV and the questions that still have to be faced are summarized.

show abstract

Anti-zika virus activity of polyoxometalates

Cited by 24 publications

References 39 publications

Punica granatum Leaf Ethanolic Extract and Ellagic Acid as Inhibitors of Zika Virus Infection

Punica granatum Leaf Ethanolic Extract and Ellagic Acid as Inhibitors of Zika Virus Infection

Anti-Zika virus and anti-Usutu virus activity of human milk and its components

Therapeutic Advances Against ZIKV: A Quick Response, a Long Way to Go

Contact Info

Product

Resources

About